Search

Your search keyword '"Mycoplasma pneumoniae isolation & purification"' showing total 116 results

Search Constraints

Start Over You searched for: Descriptor "Mycoplasma pneumoniae isolation & purification" Remove constraint Descriptor: "Mycoplasma pneumoniae isolation & purification" Topic community-acquired infections Remove constraint Topic: community-acquired infections
116 results on '"Mycoplasma pneumoniae isolation & purification"'

Search Results

2. The Epidemiology of Pathogens in Community-Acquired Pneumonia Among Children in Southwest China Before, During and After COVID-19 Non-pharmaceutical Interventions: A Cross-Sectional Study.

3. Resurgence of common respiratory viruses in patients with community-acquired pneumonia (CAP)-A prospective multicenter study.

4. Development of an immunochromatographic test for the detection of Mycoplasma pneumoniae GroES antigen.

5. Prevalence and clinical characteristics of hospitalized children with community-acquired Mycoplasma pneumoniae pneumonia during 2017/2018, Chengde, China.

6. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.

7. Investigation on Atypical Pathogens related with Community Acquired Pneumonia and the Factors Associated with Mycoplasma Pneumoniae Infection in Jiangsu, China.

8. Diagnostic utility of serology and polymerase chain reaction for detection of Mycoplasma pneumoniae and Chlamydophila pneumoniae in paediatric community-acquired lower respiratory tract infections.

9. Frequency and Clinical Presentation of Mucocutaneous Disease Due to Mycoplasma pneumoniae Infection in Children With Community-Acquired Pneumonia.

10. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016.

11. High expression of miR-222-3p in children with Mycoplasma pneumoniae pneumonia.

12. β2 microglobulin and lactate dehydrogenase are indices of different features of Mycoplasma pneumoniae-associated community-acquired lower respiratory tract infection for severity evaluation in children.

13. Impact and clinical profiles of Mycoplasma pneumoniae co-detection in childhood community-acquired pneumonia.

14. Plasma cytokine profile on admission related to aetiology in community-acquired pneumonia.

15. Are Corticosteroids Beneficial in the Treatment of Community-Acquired Pneumonia?

16. [Epidemiological and clinical analysis of community-acquired Mycoplasma pneumonia in children from a Spanish population, 2010-2015].

17. Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia.

18. Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective.

19. The Art and Science of Diagnosing Mycoplasma pneumoniae Infection.

20. A study of community-acquired Mycoplasma pneumoniae in Yantai, China.

21. Mycoplasma pneumoniae in Community-Acquired Lower Respiratory Tract Infections.

22. Detection of immunoglobulin M and immunoglobulin G antibodies to Mycoplasma pneumoniae in children with community-acquired lower respiratory tract infections.

23. Differences in inflammatory marker patterns for adult community-acquired pneumonia patients induced by different pathogens.

24. Mycoplasma pneumoniae : A significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections.

25. Detection of Mycoplasma pneumoniae and Legionella pneumophila in Patients Having Community-Acquired Pneumonia: A Multicentric Study from New Delhi, India.

26. The etiology of community-acquired pneumonia among children under 5 years of age in mainland China, 2001-2015: A systematic review.

27. Clinical presentation of Legionella pneumonia: Evaluation of clinical scoring systems and therapeutic efficacy.

28. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance.

29. Diagnosis and treatment of Mycoplasma pneumoniae in children.

30. Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis.

31. [ Mycoplasma pneumoniae : update and new challenges].

32. Serum cytokine profile contributes to discriminating M. pneumoniae pneumonia in children.

33. Measurement of lipocalin-2 and syndecan-4 levels to differentiate bacterial from viral infection in children with community-acquired pneumonia.

34. Comparison of serological methods with PCR-based methods for the diagnosis of community-acquired pneumonia caused by atypical bacteria.

35. Clinical and epidemiological characteristics in children with community-acquired mycoplasma pneumonia in Taiwan: A nationwide surveillance.

36. [Pathogen detection of 1 613 cases of hospitalized children with community acquired pneumonia].

37. Prevalence of Mycoplasma pneumoniae: a cause for community-acquired infection among pediatric populaztion.

38. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway.

39. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children: clinical features and laboratory diagnosis.

40. Mycoplasma pneumoniae infection in hospitalized adult patients with community-acquired pneumonia in China.

41. Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland.

42. The emerging role of community sentinel surveillance in the understanding of the clinical features and epidemiology of acute Mycoplasma pneumoniae infection.

43. [Mycoplasma-associated acute hepatitis in an adult patient without pulmonary involvement].

44. Atypical pneumonia.

45. Bacterial and viral etiology in hospitalized community acquired pneumonia with molecular methods and clinical evaluation.

46. [Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China].

47. [Etiologic characteristics of adult patients with community-acquired pneumonia in Beijing].

49. Community outbreak of macrolide-resistant Mycoplasma pneumoniae in Yamagata, Japan in 2009.

50. Assessment of the loop-mediated isothermal amplification assay for rapid diagnosis of Mycoplasma pneumoniae in pediatric community-acquired pneumonia.

Catalog

Books, media, physical & digital resources